Unternehmensübersicht
IN8bio, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery, development, and commercialization of gamma-delta T cell product candidates designed for the treatment of cancer and autoimmune diseases. The company functions within the healthcare sector, specifically inside the biotechnology industry, where it leverages specialized scientific expertise to advance therapeutic modalities from the laboratory phase toward potential clinical application. As of the latest available data, the enterprise carries a market capitalization of $14.28M and maintains an operational workforce consisting of 17 employees. These valuation metrics and staffing levels indicate a small-cap biotechnology firm that is currently in an early-stage development phase, characterized by a focus on capital allocation toward research and development rather than large-scale commercial revenue generation. The limited employee count relative to the biotechnology sector suggests a lean organizational structure typical of clinical-stage entities that prioritize high-value scientific output over extensive administrative overhead.
Finanzielle Gesundheit
The company reported net income of $-19,440,000 over the trailing twelve months, while EBITDA stands at $-18,090,000, reflecting significant operational losses consistent with early-stage drug development. Annual revenue and price-to-sales figures are not disclosed in the current financial dataset, yet the substantial gap between negative net income and the absence of reported revenue highlights a cost structure dominated by research expenditures and clinical trial expenses rather than operational scaling. Free cash flow is recorded at $-5,547,125, indicating that the company is burning cash to fund its development pipeline and lacks current financial flexibility to support expansion without external capital injections. All three margins—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that signifies the company has not yet achieved profitability and that any revenue generated has been entirely consumed by costs. Despite the negative earnings, the balance sheet shows a cash position of $27.09M against total debt of $2.78M, resulting in a debt-to-equity ratio of 10.10 which suggests a highly leveraged capital structure relative to equity but with ample cash reserves to cover obligations. The current ratio is 8.82, indicating that the company holds assets well above eight times its current liabilities, which points to robust short-term liquidity despite the ongoing cash burn. Return on equity is -92.5% and return on assets is -46.6%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a common characteristic of pre-commercial biotechnology firms.
Bewertungsanalyse
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive net income, while the forward P/E ratio is -0.96, implying that analysts or data providers project continued losses in the near term. The price-to-book ratio is 0.51, indicating that the market values the company at approximately half of its net book value, which often occurs with speculative biotechnology assets where intangible value is not fully captured on the balance sheet. The price-to-sales ratio is N/A as revenue data is unavailable, and the EV/EBITDA multiple is 0.56, suggesting that the enterprise value is very low relative to its negative earnings, a metric often seen in distressed or highly speculative clinical-stage firms. The stock has traded between a 52-week low of $1.17 and a 52-week high of $5.82, providing a range within which the current market price fluctuates based on clinical trial data and market sentiment. The beta value is recorded at 0.04, which indicates that the stock's price volatility is significantly lower than the broader market, though this metric requires careful interpretation given the small market cap and lack of liquidity inherent in micro-cap biotechnology securities.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings velocity against revenue expansion. Since the company does not pay a dividend, the dividend yield and payout ratio are both N/A and 0.0% respectively, reflecting a strategy where the company reinvests all available capital back into its clinical development pipeline rather than distributing income to shareholders. The absence of a dividend policy aligns with the typical lifecycle of a clinical-stage biopharmaceutical company that prioritizes funding research and development over income distribution. Consequently, the overall growth and income profile is defined by high-risk capital deployment into clinical trials with no current income generation or dividend history to support shareholder returns.